SLM3

SLM3 is an experimental nucleoside analogue that acts as a dual inhibitor of glycogen synthase kinase-3 beta (GSK-3β) and cyclin-dependent kinases (CDKs). Developed by researchers at the University of Pennsylvania, it has demonstrated potent anti-tumor activity in multiple myeloma (MM) models. Unlike traditional therapies like bortezomib, SLM3 is capable of eliminating cancer stem cell (CSC) populations, specifically the dye-effluxing side-populations that contribute to disease relapse. It induces massive apoptosis in MM cells and sensitizes them to proteasome inhibitors. The compound was identified as part of a class of c-Myc-inducing compounds that enhance the cytotoxicity of proteasome inhibitors by increasing protein translation.